Idorsia Ltd
SIX:IDIA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Idorsia Ltd
SIX:IDIA
|
CH |
|
H
|
Hyundai Engineering & Construction Co Ltd
KRX:000720
|
KR |
|
Compagnie De l'odet SE
PAR:ODET
|
FR |
|
Capgemini SE
F:CGMA
|
FR |
|
Harmonic Drive Systems Inc
OTC:HSYDF
|
JP |
|
M
|
METRO AG
XHAM:B4B0
|
DE |
|
V
|
Vietnam Export Import Commercial Joint Stock Bank
VN:EIB
|
VN |
Earnings Calls
Last Earnings Call
QUVIVIQ: Sales reached CHF 91 million, up 62% year on year, with management saying the company remains on track for full-year guidance.
U.S. reset: Idorsia said QUVIVIQ is returning to growth in the U.S. after a commercial reset to a more efficient cost base.
Growth plan: Management laid out four growth drivers: QUVIVIQ in insomnia, daridorexant beyond insomnia, TRYVIO/JERAYGO, and the pipeline.
Cash position: Idorsia said it strengthened liquidity through the Pharmakon refinancing and ended June with CHF 89 million in cash and CHF 189 million available liquidity.
TRYVIO funding: The company is in active discussions on a dedicated SPV financing structure and co-promotion model to launch aprocitentan without using Idorsia capital.
Pipeline progress: The pediatric daridorexant study was positive, lucerastat is moving toward a pivotal Fabry program, and several early-stage programs are approaching data readouts.